Sarina A. Piha‐Paul

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Artificial intelligence-guided analysis of the tumor microenvironment predicts response to pembrolizumab in rare tumors

  Journal for ImmunoTherapy of Cancer · 2026-06-01

• Prognostic value of serum tumor markers in phase I immunotherapy trials: A single-institution retrospective analysis.

  Journal of Clinical Oncology · 2026-05-28

• Biomarker study of BND-22 in combination with cemiplimab in solid tumors.

  Journal of Clinical Oncology · 2026-05-28

• Clinicopathologic and molecular characterization of <i>ARID1A</i> -mutant solid tumors using paired tissue and liquid biopsy sequencing.

  Journal of Clinical Oncology · 2026-05-28

• Career destination effects of receipt of the American Society of Clinical Oncology Young Investigator Award.

  Journal of Clinical Oncology · 2026-05-28

• Clinical outcomes of patients with PI3K pathway alterations by treatment type: The MD Anderson Cancer Center IMPACT 2 study.

  Journal of Clinical Oncology · 2026-05-27

• First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6–Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non–Small Cell Lung Cancer

  Journal of Clinical Oncology · 2026-04-20

• Abstract LB429: Impact of severe liver metastases on clinical response to immunotherapy in solid tumors

  Cancer Research · 2026-04-17

• Concordance analysis of DNA and RNA profiling: The MD Anderson IMPACT2 study in precision oncology

  Signal Transduction and Targeted Therapy · 2026-02-24

• Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson

  npj Precision Oncology · 2026-01-13 · 1 citations

• Phase I study of bevacizumab and temsirolimus combination therapy in advanced malignancies: safety, efficacy, and ovarian cancer expansion

  The Oncologist · 2025-12-11

• Presenting Features and Causes of Diagnostic Delays: A Report From the NUT Carcinoma Registry

  JCO Precision Oncology · 2025-12-01

• Table S2 from Discordance of HER2 Expression and/or Amplification on Repeat TestingPreprint

  2025-11-27

• Table S1 from Discordance of HER2 Expression and/or Amplification on Repeat TestingPreprint

  2025-11-27

• Table S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

  2025-11-26

• Figure S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

  2025-11-26

• Table 3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

  2025-11-26

• Table S6 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

  2025-11-26

• Table 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

  2025-11-26

• Table 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

  2025-11-26